JP2008024648A - Hepatic lipid reducing agent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a composition for eating/feeding capable of actively reducing the triglyceride level in the liver. <P>SOLUTION: The hepatic lipid reducing agent is an oil-and-fat composition containing an SUU-type triglyceride (S is a 20-24C saturated fatty acid residue, and U is a ≥16C unsaturated fatty acid residue) as an active component in an amount of 5-30 wt.% in the base oil-and-fat. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

  The present invention relates to a liver lipid reducing agent comprising SUU type triglyceride as an active ingredient.

  Recently, it is said to be an era of satiety, and the amount of calories ingested tends to increase with respect to the amount of calories consumed. In particular, fat accumulation in middle-aged and elderly people causes obesity and causes adult diseases such as hypertension, fatty liver, hepatitis, or cirrhosis. It has become.

  Against this background, various lipid metabolism improving agents have been proposed. For example, Patent Document 1 discloses a liver neutral fat reducing agent containing β-lactoglobulin as an active ingredient, Patent Document 2 discloses a liver lipid increase inhibitor obtained from tea leaves, and Patent Document 3 discloses The liver cholesterol and triglyceride elevation inhibitors obtained from whey proteins are shown respectively.

  On the other hand, behenic acid, which is a long-chain saturated fatty acid, is known to have a low digestive absorption rate in the digestive tract of animals due to its high melting point. A low-absorbing triglyceride containing behenic acid as a constituent fatty acid using this property is disclosed (Patent Document 4). These triglycerides can be used as a low-calorie food when used as a substitute for normal fats and oils, but the recognition of the effect is limited to the amount of behenic acid ingested without being absorbed. In addition, there is no disclosure of an example of using SUU type triglycerides in which the binding position of fatty acid to glycerin is specified at a low concentration. Moreover, there is no suggestion about liver lipid reduction.

Japanese Patent Laid-Open No. 08-259461 JP 2003-113102 A JP 2002-226394 A JP-A-1-85040

  In view of this situation, if a substance capable of more strongly promoting liver lipid reduction can be elucidated, a decrease in the amount of triglyceride in the liver makes it possible to develop a therapeutic or preventive drug or food for diabetes or arteriosclerosis. That is, an object of the present invention is to find a substance capable of reducing liver lipids and to develop an oral product useful for treatment and prevention of various diseases based on the liver lipid-reducing substance.

  In order to solve the above-mentioned problems, the present inventors have discovered for the first time that oral administration of a small amount of SUU-type triglyceride greatly reduces the amount of triglyceride in the liver. In accordance with this finding, it was found that SUU-type triglyceride can be used as an active ingredient of a liver lipid reducing agent, and the present invention was completed.

That is, the present invention is (1) a liver lipid reducing agent comprising SUU type triglyceride as an active ingredient. In the formula, S is a saturated fatty acid residue having 20 to 24 carbon atoms, and U is an unsaturated fatty acid residue having 16 or more carbon atoms.
(2) The liver lipid reducing agent according to (1), wherein S is a behenic acid residue.
(3) The liver lipid reducing agent according to (1), wherein U is an oleic acid residue.
(4) The liver lipid reducing agent according to (1), which is an oil and fat composition containing 5 to 30% by weight of SUU type triglyceride.
(5) A food containing the liver lipid reducing agent according to (1), with a health label based on the liver lipid reducing effect.
It is.

  Since the liver lipid reducing agent provided by the present invention has a high liver lipid reducing effect, it can provide functional agents and foods and drinks using the same, and can reduce the amount of triglycerides in the liver by ingestion of these. .

  Hereinafter, the present invention will be described in detail. The hepatic lipid reducing agent of the present invention is characterized by containing SUU type triglyceride as an active ingredient. The fatty acid residue indicated as S in the present invention is a saturated fatty acid residue having 20 to 24 carbon atoms, but this effect is weak for saturated fatty acids having 18 or less carbon atoms, and for saturated fatty acids having 26 or more carbon atoms, the melting point In addition, the versatility is reduced, and there are few sources of fatty acids, so it is not practical. In view of the effect and feasibility, behenic acid having 22 carbon atoms is preferred.

  The fatty acid residue indicated as U is an unsaturated fatty acid residue having 16 or more carbon atoms, but unsaturated fatty acids having 14 or less carbon atoms are not highly practical because they have few sources. The upper limit of the carbon number of U is not particularly set, but considering the supply source, it is preferably 22 or less and most preferably 18 or less. The degree of unsaturation is not particularly limited, but considering the oxidative stability of fatty acids, extremely polyunsaturated fatty acids are difficult to use, preferably unsaturated below dienoic acid, more preferably monounsaturated acids, Oleic acid is most preferred.

  The active ingredient of the present invention is represented by the SUU type in which the fatty acid residue represented by S is ester-bonded to the hydroxyl group at the 1- or 3-position of glycerol, and the fatty acid residue represented by U is ester-bonded to the remaining two hydroxyl groups of glycerol. 1 long chain saturated-2 long chain unsaturated triglyceride. In addition, in the notation of this invention specification, the 1st position and the 3rd position are not distinguished about the coupling | bonding position to the glycerol of a fatty acid.

  The present invention is characterized by containing a small amount of SUU-type triglyceride in fats and oils. And by this oral intake, the amount of triglycerides in the liver can be reduced without significantly affecting the digestibility. The effective intake as a liver lipid-reducing agent varies depending on the purpose of use, the target of use, and the form. Can do.

  When SUU-type triglycerides are present in oils and fats in excess of 30% by weight, other effects due to low digestion and absorption such as a decrease in calorie intake are exhibited, and problems such as absorption inhibition of fat-soluble vitamins occur. Furthermore, the melting point of the oil and fat composition containing SUU-type triglyceride is increased, and the versatility is lacking. Further, if it is 5% by weight or less in fats and oils, the effect relating to the decrease in the amount of triglycerides in the liver is not clearly shown, so that it is inappropriate.

  The present invention is characterized by containing a small amount of SUU type triglyceride in fats and oils, but the base fats and oils are edible animal and vegetable fats and oils such as soybean oil, sunflower oil, rapeseed oil, canola oil, rice bran oil, safflower oil, palm Oil, palm kernel oil, coconut oil, fish oil, milk fat, cocoa butter, etc. are not limited. In many drugs, ingestion in excess of the proper amount may cause safety problems, whereas the active ingredient of the present invention is a triglyceride using natural plant-derived ingredients. From the viewpoint of safety, the upper limit of intake is hardly a problem.

  The SUU type triglyceride which is an active ingredient of the present invention is a fatty acid or ester of a highly hardened oil of Hyelin rapeseed oil or fish oil, or further purified by distillation, using a general unsaturated fatty acid as a source of S fatty acid. By using a lipase having a specificity at positions 1 and 3 as a fatty acid source such as rapeseed oil, canola oil, soybean oil, sunflower oil, safflower oil, hyolein sunflower oil, hyolein safflower oil, etc. Obtained by transesterification. The obtained active ingredient can be concentrated by solvent fractionation, which is preferable.

  The hepatic lipid reducing agent of the present invention can be used for various uses of foods, drugs or feeds. The form at that time varies depending on the melting point of the base oil and fat and the addition amount of the SUU type triglyceride of the present invention, but the form in which the liquid oil is used as it is, the form of a liquid such as emulsion or suspension, cream, margarine, shortening, hard It can take the form of common food ingredients such as butter. The food using the liver lipid reducing agent is preferably a food having a relatively high fat content, and can be blended in, for example, mayonnaise, dressings, various creams, chocolate, and the like. In addition, it can mix | blend with confectionery, such as baked confectionery, bread, etc., and can also be used as a capsule.

  The intake standard of the liver lipid reducing agent of the present invention and foods containing the same is not particularly set, and it can be used in place of normal foods and oil / fat compositions in foods to obtain liver lipid reducing effects. it can. Examples of the intake of the liver lipid reducing agent to be targeted include 5 to 100 g, preferably 10 to 50 g per day.

  Examples of the present invention will be described below, but the technical scope of the present invention is not limited by these examples. In the following, “%” means “% by weight” unless otherwise specified.

[Production Example 1]
A highly hardened oil of high erucin rapeseed oil containing 45% of unsaturated fatty acids having 22 carbon atoms was hydrolyzed and esterified to obtain fatty acid ethyl ester. This fatty acid ester was rectified to obtain a fraction containing 97.9% of a saturated fatty acid ester having 20 to 24 carbon atoms in the acyl group. 70 parts of this fatty acid ester fraction was mixed with 30 parts of high oleic sunflower oil, transesterified using a 1,3-position specific enzyme agent, and then the fatty acid ester was distilled off to give an iodine value of 45. A reaction oil was obtained. Further fractionation was performed, and the low melting point fraction was collected at a yield of 42.4% and purified by a conventional method (test fat and oil). The test fats and oils have a melting point of 24 ° C. and an iodine value of 55.8. The fatty acid composition and triglyceride (TG) composition are shown in Table 1.

(Table 1) Fatty acid and triglyceride composition of test fats and oils

[Test Example 1]
The effect of the test fats and oils on the amount of triglycerides in the liver was investigated by animal experiments. Twelve 7-week-old SD male rats (sold by Japan SLC Co., Ltd.) were used as model animals. After one week of preliminary breeding, the group was divided into a comparative oil and fat group (6 animals) and a test oil and fat group (6 animals) so that the average body weights between groups were almost equal. The dietary feed was 28% fat based on the AIN-93G composition. These were ad libitum for 6 weeks. The diet composition is shown in Table 2 below.

(Table 2) Test meal composition

  Six weeks later, blood was collected from the abdominal aorta and the liver weight and liver lipid were measured. For measurement of liver lipid, 0.5 g of liver was weighed, lipid was extracted by the Folch method, and liver triglyceride (neutral fat) was measured by the method of Fletcher et al. As shown in Table 3, the replacement of SUU type triglyceride showed a decrease of about 2.2% in liver weight and 10.1% in liver neutral fat. From the above results, it was shown that SUU type triglyceride has liver lipid reducing action.

(Table 3) Liver weight, liver triglyceride content and fecal production rate

[Example 1] Production of mayonnaise While mixing 30 parts of egg yolk with 25 parts of vinegar, 4 parts of salt and 1 part of sodium glutamate, and separately stirring 28 parts of test oil prepared in Production Example 1, 112 parts of rapeseed oil Mayonnaise having a liver lipid reducing effect can be prepared by gradually adding mixed oil mixed with.

[Example 2] Production of cream In 51 parts of water, 4 parts of skim milk powder, 9 parts of test oil prepared in Production Example 1, 36 parts of milk fat, 0.2 part of sugar ester, 0.2 part of lecithin, sodium hexametaphosphate 0 .1 part of the mixed solution is heated to 70 ° C., stirred with a homomixer (manufactured by Tokushu Kika Kogyo Co., Ltd.) at 10,000 rpm for 1 minute, and pre-emulsified. Next, this solution is homogenized using a high-pressure homogenizer under a force of 10 kgf / cm 2 and then sterilized by heating at 144 ° C. for 4 seconds. This solution is rapidly cooled to 5 ° C. and then aged at 5 ° C. overnight to prepare a cream having a liver lipid reducing effect.

Claims (5)

A liver lipid reducing agent containing SUU type triglyceride as an active ingredient. In the formula, S is a saturated fatty acid residue having 20 to 24 carbon atoms, and U is an unsaturated fatty acid residue having 16 or more carbon atoms. The liver lipid reducing agent according to claim 1, wherein S is a behenic acid residue. The liver lipid reducing agent according to claim 1, wherein U is an oleic acid residue. The liver lipid reducing agent according to claim 1, which is an oil and fat composition containing 5 to 30% by weight of SUU type triglyceride. The food containing the liver lipid-reducing agent according to claim 1, with a health label based on a liver lipid-reducing effect.